The Child Advocate
Home
What'sNew
Subjects
Contents
Feedback
Search
Approaches
to the Reduction of Relapse Rates in Persons with Anorexia Nervosa
August 2001
Contributed by Michele A.
Soltis, Penn State College of
Medicine
“I am only one; but still I am
one. I cannot do everything, but
still I can do something.
I will not refuse to do the something I can do.”
---Helen Keller
With these words, the diligent, sedulous, tireless Helen Keller conveys
her belief that persistence, determination, and an unwillingness to settle,
surrender, or accept complacency can enable one to overcome immense obstacles,
to achieve great goals, or, at the very least, to offer one’s seemingly
minute contribution to the realization of a purpose larger than oneself.
By adopting such an outlook, we too can aspire to accomplish those aims
which elude us. Whether our focus is on personal strivings or professional
endeavors, endurance, perseverance, and steadfastness can assist us in our
attempts to actualize our objectives. It
is with this mindset that the committees for Healthy
People 2010 seek to understand and improve the health and well being of
the public at large.
The development of goals and objectives for the advancement of Public
Health issues is central to the work of Healthy
People. Few such goals are measurable, meaning that the objectives for a given area of Public
Health interest are intended to provide “direction for action” in moving
towards the fulfillment of a desired, stated end. Areas of interest for which measurable goals are proposed
have previously been investigated and evaluated.
As a result, relevant data representative of local, state, or even
national populations exists and can serve as a scaffolding to be built upon in
future studies. Other objectives
are developmental, denoting an array
of Public Health topics which are of emerging importance and for which little
or no baseline data exists. It is
the intent of Healthy People to
present such goals and objectives which “provide a vision” for a favored
outcome or health status. All Healthy People objectives, whether they be measurable or
developmental, must promise value and importance to the Public Health sector.
The objectives should be prevention oriented in nature, should be
designed to encourage action, must be supported by scientific evidence, and
should afford opportunity for continuity and comparability.
One such area of the Public Health arena considered by Healthy People deals directly with topics encompassed under the
umbrella of mental health.
According to Healthy People, mental health cannot be thought of simply as an “absence
of mental illness”. Instead, it
must be recognized as a condition where successful, prosperous mental
functioning prevails. Mental
health results in fruitful, prolific activities, flourishing personal
relationships, and the devices to adapt to and cope with change,
disappointment, grief, and adversity.
Mental health is imperative to an individual’s sense of well being,
fulfillment, and interaction with society.
On
the flip side, mental disorders
connote a faltering in mental health, characterized by derangements in thought
processes, behaviors, and moods. Mental
disorders may significantly impair one’s ability to function as a productive
member of society, and may result in the deterioration of one’s personal
relationships and perception of self. The
term, mental illness, collectively
refers to all of the diagnosable mental disorders.
Unfortunately,
an estimated 22% of the U.S. population is plagued by the onset of mental
illness in a given year, placing a tremendous burden of disability on the
community as a whole. Regrettably,
this amount of disability and hardship has gone under recognized, if not
unrecognized altogether. The
landmark study, Global Burden of Disease,
sponsored by the World Health Organization and Harvard University, has
demonstrated that mental illness is nearly equivalent to both heart disease
and cancer as a cause of incapacity in industrialized nations.
It should be noted that suicide, a leading Public Health concern, is
most often attributable to the devastating toll mental illness can take.
Mental
illness has been shown to affect people of all ages, genders, races, and
socioeconomic groups. Children
and adolescents comprise an ever-increasing subset of the population diagnosed
with mental disorders. In a given year, one in five children and adolescents
between the ages of 9 and 17 are diagnosed with a mental disorder, a
behavioral disturbance, or a serious emotional disorder.
An estimated 5% of such diagnosed children and adolescents are severely
impaired by their illness. Such
mental illness may lead to further difficulties with substance abuse, suicide
contemplation and completion, and criminal activity. At the other end of the age continuum, approximately 25% of
older Americans suffer with mental disorders such as depression, anxiety, and
dementia. These said disorders
lie outside of what is considered normal aging.
There
is promising news in that a plethora of highly effective treatments have
recently become available for the palliation of most mental disorders.
Such said treatments range from myriad pharmacotherapies to various
psychotherapies and even to electroconvulsive therapies.
Sadly, recent studies have indicated that only a mere 25% of persons
diagnosed with a mental disorder receives medical help in combating their
illness. A major measurable
objective for the Healthy People 2010
initiative focuses on the need for psychiatric or psychological treatment to
be made readily available to inflicted individuals.
Such measures may help to substantially reduce the staggering $80
billion spent per year on disability insurance payments, lost productivity,
property loss, crime, and other costs attributed to the detrimental effects of
untreated mental illness. In
addition to ensuring widespread, accessible treatment for the rehabilitation
of those with mental illness, Healthy
People strives to eradicate the discrimination and prejudices which plague
individuals diagnosed with mental illness.
Such stigmas serve only to present a formidable obstacle to those in
dire need of treatment.
It
should be noted that as the life expectancy of individuals continues to grow
longer, those with untreated mental disorders might live longer, causing the
prevalence of mental illness to continue to increase as well.
This ballooning in prevalence will inevitably present daunting
challenges in financing, organizing, and delivering much needed mental health
care. Taking steps forward today
to continue to ensure adequate funding and accessible care will surely make
for the ready availability of mental health services tomorrow.
The Healthy People 2010
initiative toils to improve mental health and ensure access to adequate,
appropriate, quality mental health care.
In seeking to do so, the initiative has turned its attention to
specific issues concerning mental disorders such as schizophrenia, major
depression, manic depression, substance abuse and other addictive disorders,
panic disorders, obsessive-compulsive disorder, specific phobias, eating
disorders, dementia, and post-traumatic stress disorder.
Endeavors to be pursued, as cited by Healthy
People, include the creation and implementation of preventive
interventions and the promotion of further social and behavioral research.
This research will target the delineation of the possible interweaving
of biological, psychological, and environmental processes which may contribute
to the manifestation of mental disease. Other
quests include the development of better stress management techniques, coping
skills, community support programs, and treatment modalities.
Together, such efforts can hopefully help to alleviate the tremendous
burden of disease and disability associated with mental illness.
I would now like to shift the focus from the Healthy
People 2010 objectives for mental illness in general, to the Healthy
People intentions pertaining to one mental disorder in particular. In an
effort to curb the devastatingly adverse sequelae of eating disorders, Healthy
People has elected to target the evolution of approaches which will
hopefully serve to reduce the relapse rates for persons suffering with
anorexia nervosa. Currently,
little information is available regarding the prediction of clinical course,
outcome, and potential for relapse in those patients afflicted with this
disease. Attaining such
information is complicated by the very complexity of the disorder itself, a
dearth of shared terminology and communicative means among those researching
this disease, and a paucity of controlled clinical treatment studies and
subsequent follow-up investigations. The
Healthy People developmental
objective aims to cultivate and assess specific interventions that can perhaps
prevent relapse after recovery in patients diagnosed with anorexia nervosa.
It is hoped that by decreasing or altogether eliminating the chance of
relapse, such afflicted individuals may enjoy a better long-term prognosis and
a fuller life.
Anorexia Nervosa is a serious, devastating disease often associated
with a chronic course, significant morbidity, and a considerable mortality
rate of up to 11%. This eating
disorder is characterized by an intense fear of gaining weight, a colossal
over-concern with body image and size, and by profound disturbances in eating
behaviors aimed at maintaining a low body weight.
Most patients go to extreme lengths to carry out their strange,
ritualistic dining patterns in secrecy. Patients
with this disease place an excessive amount of importance on body size,
allowing their weight to be the sole measure of their personal worth.
Such perceptual derangements lead patients to become dangerously
emaciated. Anorexia Nervosa can
be diagnosed when the body weight falls 15% or more below the individual’s
ideal weight as based on height, age, and gender. According to the Diagnostic
and Statistical Manual of Mental Disorders—4th Edition,
diagnosis is also contingent on the disturbance of the menstrual cycle in
postmenarchal women. The
diagnostic criteria state that a postmenarchal woman must be amenorrheic for
at least three consecutive menstrual cycles to be considered anorexic.
The prevalence of Anorexia Nervosa is between 0.5 and 1% among all
women aged 15-50. Over 90% of all
anorexic patients are female. However,
an estimated one million men have been diagnosed with the disorder as well.
Anorexia is most frequently found in men who are wrestlers, dancers, or
homosexuals. Given that a great
deal of emphasis is placed on one’s physical appearance in the gay
community, some gay men are led to zealously pursue the thin body ideal.
Average age of onset of this disease is age 17, for both sexes.
Onset is rare before puberty or over the age of 40.
This disease has been found to be more common in industrialized
societies and in higher socioeconomic classes.
The classic anorexic patient is usually an older adolescent girl who is
bright, does well in school, is athletic, usually popular with peers, hails
from an upper-middle class family, and is not objectively fat.
She may however be a tad bit overweight, and so she begins a dieting
regimen---only to soon slip into the downward spiral characteristic of
anorexia nervosa.
The etiologies of this eating disorder remain an enigma, though many
theories attempting to speculate on the causes of Anorexia Nervosa abound.
Psychological hypotheses propose that patients may have an immense fear
of losing control, may have a poor self-image, may dread the thought of
developing adult secondary sexual characteristics and the adult
responsibilities that accompany that bodily development, and/or the patient
may suffer from the “all or none” way of thinking frequently associated
with a borderline personality disorder (e.g. one is either fat or thin, there
is no healthy “in-between”).
It has been postulated that many anorexic patients are entwined in
suffocating relationships with their families---the self-starvation may be one
way in which the patient can assert control over her body, and so seemingly,
gain control over her life as well.
Though not specific to eating disorders, past physical and/or sexual
abuse may be a risk factor for the development of Anorexia Nervosa.
Social theories hypothesize that societal opinions, which tend to
equate a waif-like figure with attractiveness, drive women to develop eating
disorders. Such supposed
ideologies may in fact be responsible for a small subset of the anorexic
patient population---after all, this disease is more common among women who
are models, ballerinas, and gymnasts. However,
it should be noted that accounts of this disease have been found dating back
to periods when societal norms for beauty were very much different---as
evidenced by the rotund, robust figures of the women captured in Rembrandt’s
Baroque-era paintings.
Familial and genetic data support a heritable basis for this disease.
Family studies reveal an increased incidence in both mood disturbances
and eating disorders among first-degree relatives of anorexic patients.
Twin studies show higher concordance rates for monozygotic versus
dizygotic twin pairs. Neuroendocrine
evidence suggests a biological contribution to the disease, citing aberrations
in levels of circulating corticotropin-releasing factor and reduced central
nervous system norepinephrine metabolism.
Clinically, anorexic patients do not suffer a loss of appetite; their
refusal to eat is in response to their profound fear of gaining weight. Individuals with anorexia nervosa commonly exercise intensely
to lose weight and alter their body shape.
Some may primarily restrict food intake as a primary means of weight
control (the restricting type of anorexia nervosa), while others employ
bingeing and purging to keep the pounds off (the purging type of anorexia
nervosa).
Amenorrhea, resulting from decreased secretion of gonadotropin-releasing
hormone and subsequent decreased secretion of both leutinizing and
follicle-stimulating hormones, is so common that its presence is a diagnostic
feature of this disorder. Other
common findings include decreased thyroid hormone release, and thus resultant
bradycardia, intolerance to cold, and constipation.
The skin may become dry, scaly, and covered in lanugo, or the skin may
have an orange-yellowish tint to it due to increased levels of carotene in the
blood. Osteoporosis ensues, owing
to the decreased levels of estrogen.
Anemia, lymphopenia, hypo-albuminemia, and hypokalemia may occur---the
latter contributing to the anorexic patient’s increased susceptibility to
cardiac arrhythmia and sudden cardiac death.
Primary management of this patient is directed at the presenting
symptoms. All medical
complications must be carefully treated and followed.
During starvation, psychotherapy is often of little benefit due to the
cognitive impairment that often accompanies the malnourished state.
When patients have stabilized, a therapeutic program, including
supervised meals, weight and electrolyte monitoring, psycho-education
regarding their illness, nutritional counseling, and individual and family
therapy is implemented. Antidepressants
are also usually prescribed to treat co-morbid depression.
Clinical recovery does occur in 50-70% of all patients diagnosed with
anorexia nervosa who are privy to treatment.
Clinical Recovery is defined as:
1)
the achievement and
maintenance of a body weight that is at least 85% of what is considered to be
the individual’s ideal body weight given the individual’s height, age, and
gender
2)
the resumption of
menstrual periods in women
3)
the full development
of secondary sexual characteristics in both males and females
4)
the cessation of
restrictive and/or purging behaviors
5)
the termination of
maladaptive attitudes regarding dietary habits
6)
the demonstration of
satisfactory interpersonal relationships
To
be considered “recovered”, all of the above criteria must be met and
maintained for no less than twelve months.
Studies have estimated that time to clinical recovery
may average between 57-79 months, depending on the individual patient.
Studies have suggested that almost 30 to 50% of all patients thought to
be successfully treated become ill again within 1 year of achieving clinical
recovery. After this first, most
difficult post-recovery year, patients may still relapse at the rate of 3% per
year. The overall relapse rate is currently about 20%.
Relapse
is defined as:
1)
the failure of the
patient to maintain a body weight that is at least 85% of what is considered
to be the individual’s ideal body weight given the individual’s height,
age, and gender.
2)
the cessation of
menstrual periods in women
3)
the resumption of
restrictive and/or purging behaviors
4)
the resumption of
maladaptive attitudes regarding dietary habits
Relapse can occur only after the achievement of
clinical recovery, as previously defined.
Prognostic predictive factors which may indicate a likelihood
for a patient to relapse have been tirelessly sought. Researchers have managed to detect and agree on very few such
predictive factors. It has been
found that those patients with long duration of illness, those that present
for treatment at an extremely low body weight, patients who are of more
advanced age at clinical presentation, and those that exhibit purging
behaviors are more susceptible to relapse and poorer outcome.
As previously noted, an escalation in the efforts to develop and assay
treatment modalities that may help to prevent relapse in these patients is
needed. To date, psychiatrists
and psychotherapists have been touting a particular kind of psychotherapy,
cognitive-behavioral therapy, which may help to reduce relapse rates in
anorexics treated with this rehabilitation method.
Other studies have demonstrated the efficacy of certain
pharmacotherapies in lowering relapse rates after recovery in these patients.
Let
us now take a closer look at these promising, ongoing investigations:
Another
promising approach attempting to reduce the relapse rates in persons with
anorexia nervosa involves the use of the anti-depressant medication,
fluoxetine. Fluoxetine, or
Prozac, is a selective serotonin reuptake inhibitor, primarily prescribed for
those individuals suffering from depression.
However, when used in patients recovering from anorexia, the drug has
been shown to assist in the prevention of relapse.
Studies performed at the University of Pittsburgh demonstrate that an
estimated 62% of patients treated with Prozac for this purpose have maintained
their weight at or above 85% of their desired body weight for over one year.
It is important to realize that the Prozac does not treat the eating
disorder itself. Investigators have hypothesized that the anti-depressant
helps to thwart obsessions, compulsions, depression, and anxiety in these
patients, all of which can provoke a relapse.
The Prozac is most effective once the patient has regained weight and
is well on her/his way to recovery. It
should also be noted that restricting-type anorexics appeared to benefit more
from this therapy than restricting-purging type anorexics. This finding raises the possibility that disturbances in
serotonin activity may be somewhat responsible for this disorder, perhaps
creating a vulnerability for this illness in susceptible individuals.
Further investigations are warranted to fully examine the role that
serotonin receptors and other neurochemical activities may play in the
pathogenesis of anorexia nervosa.
The question of whether or not eating disorders can be prevented is
also an area of ongoing debate and research.
One study evaluated a pilot school-based eating disorder prevention
program designed to discourage and reduce dietary restraint among junior-high
school age girls. The students’
attitudes and behaviors regarding dietary habits were evaluated both before
and after completing the prevention program.
Study results indicate that the students reported an increase
in dietary restraint behaviors after
completing the prevention program. This
may imply that such “prevention programs” may actually be doing more harm
than good.
Aside
from formal prevention programs, paying careful attention to remarks made
about a patient’s or child’s weight, no matter how innocuous the comments
may seem, may really make all the difference.
Another
proposition regarding an approach to reducing relapse rates in anorexics
involves the at-home monitoring of these patients by a Community Psychiatric
Nurse after the patient’s discharge from an inpatient or outpatient
treatment program. The Community
Psychiatric Nurse may offer support and nutritional counseling in maintaining
the patient’s weight gain, may effectively discourage the patient from
engaging in any restricting and/or purging behaviors, and may reinforce the
therapeutic principles implemented during the patient’s CBT sessions.
Studies are currently underway in the United Kingdom to assess the
effectiveness and practicality of such an approach.
Other intended research will focus on the efficacy of alternative
treatment modalities, such as family therapy sessions, advanced nutritional
rehabilitation and counseling, and other various methods of psychotherapy,
such as interpersonal therapy, which may help to further modify behaviors and
dysfunctional attitudes. Studies examining the use of a sundry of different
psychotropic medications in the hopes of reducing the rate of relapse among
recovered anorexic patients are also underway.
The necessity of timely diagnosis and effective treatment of co-morbid
psychiatric conditions is becoming increasingly apparent as well.
In
addition, there is a great need for future studies that possess the following
methodological strengths: For instance, although the prevalence of this
disease is admittedly small, studies utilizing prospective sampling and data
collection may prove to be beneficial in investigating this malady.
Such a prospective study may be less susceptible to recall and report
errors and biases. Relative
risks, attributable risks, and the numbers needed to treat may demonstrate the
statistical significance of such a study. Multiple variable analyses and
subgroup analyses may assist in adjusting for potential confounding variables.
Such studies may also be well suited for verifying prior associations
in the cause-effect relationship, extrapolating relevant data to similar
groups, and even extrapolating beyond the data and to other populations
outside the study populace.
Other
future research endeavors may find that studying shorter intervals between
follow-up periods and using the direct patient interview as a means of data
collection may strengthen the said investigation.
Explicit, well-defined inclusion criteria is needed to better
characterize the study population and to narrow the group to which the study’s
results can be immediately applied or extrapolated.
More
appropriate, useful signification of outcome measures is also needed. This
includes the demand for universally accepted, standardized definitions for
terms such as recovery, remission, relapse, and recurrence.
Larger sample sizes, which can be followed for extended
periods of time, may allow a reasonable chance of demonstrating a
statistically significant difference between study groups if, in fact, a
difference actually does exist in the larger population from which the study
samples were drawn. Such larger
study samples may posses great statistical power and hence little type II
error if in fact, the study’s hypothesis is found to be true.
Lastly, future studies
must better qualify the presentation and duration of the index episode,
subsequent symptom-free intervals, and later periods of clinical recovery,
recurrence, and relapse using longitudinal methods of data evaluation.
Life tables, which allow for the examination of the experience of many
groups of individuals over time, may be used.
Examples of such longitudinal life table methods include the
Kaplan-Meier and the Cutler-Ederer tables. Regression models, which may
describe the association between one dependent variable and one or more
independent variables can also be utilized in this capacity.
Such regression techniques may as well prove to be helpful in adjusting
for confounding variables.
With our renewed, resolute, unflagging determination and steadfast effort, perhaps answers can be found to the myriad questions posed by this devastating disease. Perhaps this next decade will bring prolonged, permanent recovery and relief to those wasting away at the hands of this practically silent, secretive killer. Perhaps we can help to provide those suffering, emaciated souls with hope for tomorrow and the promise of a new day. We cannot refuse to do the something we can do.
Bibliography:
1)
Beaumont, P., et
al. Treatment of Anorexia Nervosa.
Lancet, 1993, 341: 1635-40.
2)
Calvo, S., et
al. Between 5 and 9 Years’ Follow-up in the Treatment of
Anorexia Nervosa. Psychotherapy & Psychosomatics, 1989, 52:133-9.
3)
Carter, J., et
al. Primary Prevention of Eating Disorders: Might it Do More Harm
Than Good? International Journal of
Eating Disorders, 1997, 22: 167-72.
4)
Deter, H., and
Herzog, W. Anorexia Nervosa in a
Long-term Perspective: Results of the Heidelberg-Mannheim Study.
Psychosomatic Medicine, 1994,
56: 20-7.
5)
Eckert, E., et
al. Ten-year Follow-up of Anorexia Nervosa: Clinical Course and
Outcome. Psychological Medicine, 1995, 25: 143-56.
6)
Foppiani, L., Luise,
L., et al.
Frequency of Recovery from Anorexia Nervosa of a Cohort of Patients
Re-Evaluated on a Long-Term Basis Following Intensive Care.
Eating and Weight Disorders, 1998, 3: 90-4.
7)
Gillberg, I., et
al. Anorexia Nervosa Outcome: A Six-year Controlled Longitudinal
Study of 51 Cases Including a Population Cohort. Journal of the American
Academy of Child and Adolescent Psychiatry, 1994, 33: 729-39.
8)
Herzog, D., et
al. Outcome in Anorexia Nervosa and Bulimia Nervosa.
A Review of the Literature. Journal
of Nervous and Mental Disease, 1988, 176: 131-43.
9)
Herzog, D., et
al. Recovery and Relapse in Anorexia and Bulimia Nervosa: A 7.5
Year Follow-up Study. Journal of the American Academy of Child and Adolescent Psychiatry,
1999, 38: 829-37.
10)
Isager, T., et
al. Death and Relapse in Anorexia Nervosa: Survival Analysis of
151 Cases. Journal of Psychiatric Research, 1985, 19: 515-21.
11)
Kaye, W., et
al. Double-blind Placebo-controlled
Administration of Fluoxetine in Restricting and Restricting-purging Type
Anorexics. Biological
Psychiatry, 2001, 49: 644-52.
12)
Kennedy, S., and
Garfinkel, P. Advances in
Diagnosis and Treatment of Anorexia Nervosa and Bulimia Nervosa.
Canadian Journal of Psychiatry,
1992, 37: 309-15.
13)
Meades, S.
Suggested Community Psychiatric Nursing Interventions with Clients
Suffering from Anorexia Nervosa and Bulimia Nervosa.
Journal of Advanced Nursing, 1993, 18: 364-70.
14)
Peterson, C., and
Mitchell, J. Psychosocial and
Pharmacological Treatment of eating Disorders: A Review of Research Findings.
Journal of Clinical Psychology, 1999, 55: 685-97.
15)
Pike, K. Long-term
Course of Anorexia Nervosa: Response, Relapse, Remission, and Recovery.
Clinical Psychology Review, 1998, 18: 447-75.
16)
Strober, M., et
al. The Long-term Course of Severe Anorexia Nervosa in
Adolescents: Survival Analysis of Recovery, Relapse, and Outcome Predictors
Over 10-15 Years in a Prospective Study.
International Journal of Eating Disorders, 1997, 22: 339-60.
17)
Touyz, S., and
Beumont, P. Anorexia Nervosa: A Follow-up Investigation.
Medical Journal of Australia,
1984, 141: 219-22.
18)
U.S. Department of
Health and Human Services. Healthy
People 2010. 2nd ed. With Understanding and Improving Health and
Objectives for Improving Health. 2 vols. Washington, DC: U.S. Government Printing Office, November
2000.
19) Zipfel, S., et al. Long-term Prognosis in Anorexia Nervosa: Lessons from a 21-year Follow-up Study. Lancet, 2000, 355: 721-22.
Return to Eating Disorders page
![]()
Home
What'sNew
Subjects
Contents
Feedback
Search
The Child Advocate Relapse in Anorexia Page.
Copyright © 2001-2008 The Child Advocate All rights reserved.
Revised: January 20, 2008
.